Viewpoint Chief Science Officer, Michael K Schultz PhD receives Distinguished Inventor Award at the University of Iowa Innovation Summit.
April 23, 2013
Michael K Schultz PhD, CSO and Assistant Professor of Radiology at the University of Iowa received a distinguished Inventor Award today for a 2012 patent submission of a new targeted therapy for metastatic melanoma. The technology targets specific metabolic properties that differentiate cancer cells from normal healthy cells. The discovery is based on developing a more detailed understanding of differences in mitochondrial oxidative metabolism, dysfunctional mitochondrial electron transport chain activity in cancer cells and resultant heightened levels of oxidative stress that are characteristic of cancer cell relative to normal healthy cells. The discovery is driving the development of a new platform technology for targeting cancer cells and metastatic melanoma for image-guided therapy that is in preclinical development at Viewpoint Molecular Targeting, LLC.